Herpes Zoster Infection Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Prescription Treatment is the fastest growing sector, North America is the largest market

The Global Herpes Zoster Infection Treatment Market is projected to expand from USD 271.12 Million in 2025 to USD 341.47 Million by 2031, achieving a Compound Annual Growth Rate of 3.92%. This market encompasses various therapeutic and preventative approaches, including antiviral pharmacotherapies, analgesic agents for managing neuropathic pain, and recombinant vaccines aimed at preventing the varicella-zoster virus. Key drivers fueling this growth include the escalating rate of global immunosenescence within the aging population, which naturally diminishes cell-mediated immunity and heightens susceptibility to viral reactivation.

Additionally, the increasing incidence of shingles among immunocompromised individuals and strong public health campaigns advocating for adult immunization schedules are fundamental catalysts for sustained market demand. Nevertheless, the market faces a significant hurdle due to the high cost associated with advanced recombinant vaccines and long-term pain management therapies, which limits accessibility in cost-sensitive regions. This economic barrier hinders widespread adoption and adherence to optimal treatment protocols, potentially impeding revenue growth in emerging economies.

For instance, in 2025, an estimated 10% to 18% of individuals diagnosed with herpes zoster developed postherpetic neuralgia, a complication demanding prolonged and often expensive medical intervention. The primary demographic engine for the market is the rapidly aging global population, which necessitates expanded prophylactic measures and state-sponsored immunization protocols. As immunosenescence weakens the natural defense against the varicella-zoster virus in older adults, governments are increasingly integrating shingles vaccinations into public health subsidies to mitigate the long-term economic burden of complications.

This structural shift is exemplified by major policy updates in regions with high geriatric densities, where subsidized access directly correlates with market volume expansion, as seen in Japan's decision to include shingles vaccines in its national immunization program for individuals aged 65 and older from FY2025. This regulatory support effectively translates high latent demand into active revenue streams for manufacturers, bolstering market sustainability. Furthermore, continuous advancements in antiviral therapeutic pipelines and next-generation vaccine technologies are dynamically reshaping the competitive landscape by addressing unmet needs regarding tolerability and administration efficiency. Pharmaceutical developers are focusing on formulating improved candidates that offer comparable efficacy to existing standards while reducing the severity of local adverse events, thereby enhancing patient compliance. This progress is underscored by developments such as Curevo Vaccine's adjuvanted subunit vaccine candidate achieving a 100% vaccine response rate one month after the second dose in a Phase 2 trial. These clinical innovations are crucial for capturing the substantial portion of the unvaccinated population, especially considering that as of 2024, the cumulative immunization penetration rate in the US had only reached 39% of the recommended adult population.

Market Drivers

The rapidly aging global population serves as the primary demographic engine for the market, necessitating expanded prophylactic measures and state-sponsored immunization protocols. As immunosenescence weakens the natural defense against the varicella-zoster virus in older adults, governments are increasingly integrating shingles vaccinations into public health subsidies to mitigate the long-term economic burden of complications. This structural shift is evidenced by major policy updates in regions with high geriatric densities, where subsidized access directly correlates with market volume expansion.

According to Pharma Japan, in December 2024, the Japanese health ministry approved a plan to include shingles vaccines in the national immunization program for individuals aged 65 and older from FY2025. This regulatory support effectively converts the high latent demand within the aging demographic into active revenue streams for manufacturers, ensuring market sustainability despite economic fluctuations. Advancements in antiviral therapeutic pipelines and next-generation vaccine technologies are continually reshaping the competitive landscape by addressing unmet needs regarding tolerability and administration efficiency.

Pharmaceutical developers are prioritizing the formulation of improved candidates that offer comparable efficacy to existing standards while reducing the severity of local adverse events, thereby improving patient compliance. Demonstrating this progress, according to Curevo Vaccine, in January 2024, their adjuvanted subunit vaccine candidate achieved a 100% vaccine response rate one month after the second dose in a head-to-head comparison in a Phase 2 trial. These clinical innovations are critical for capturing the significant portion of the unvaccinated population, particularly as GSK reported in 2024 that the cumulative immunization penetration rate in the US had only reached 39% of the recommended adult population.

Market Challenges

The high cost structure associated with advanced recombinant vaccines and long-term pain management therapies constitutes a formidable barrier to the expansion of the Global Herpes Zoster Infection Treatment Market. This economic impediment severely restricts market penetration, particularly in emerging economies and cost-sensitive regions where healthcare budgets are tightly constrained. Although the clinical necessity for effective shingles prevention is rising due to global aging, the substantial financial investment required for multi-dose vaccine regimens often deters both individual patients and institutional payers.

Consequently, manufacturers encounter significant difficulties in converting the high volume of at-risk individuals into actual revenue, as the prohibitive pricing compels many to forego necessary preventative care or treatment. This affordability gap creates a fragmented market landscape where growth is largely confined to nations with robust reimbursement frameworks, leaving vast potential markets untapped.

The direct correlation between high costs and low uptake stifles the industry's ability to capitalize on the increasing prevalence of the virus. According to the International Federation on Ageing, in 2025, the significant out-of-pocket expense of approximately $150 per dose remained a primary barrier, resulting in vaccination coverage rates of just 32.9% in jurisdictions lacking public funding. Such low adherence figures demonstrate how pricing barriers directly hamper the market's trajectory and limit sustained revenue generation.

Market Trends

The two most significant trends in the Global Herpes Zoster Infection Treatment Market are the research into next-generation adjuvant systems and the transition toward recombinant subunit vaccine dominance. Research into Next-Generation Adjuvant Systems for Improved Tolerability is reshaping the prophylactic landscape by addressing the high reactogenicity associated with current standard-of-care vaccines. Industry players are prioritizing the development of proprietary adjuvant formulations, such as CpG 1018, which aim to maintain high immunogenicity while significantly reducing local and systemic adverse events.

This focus on optimizing the safety profile is critical for overcoming vaccine hesitancy and improving uptake rates in the elderly population. According to Dynavax Technologies Corporation, in August 2025, in a press release regarding Phase 1/2 trial results, their Z-1018 candidate demonstrated a 100% humoral vaccine response rate one month after the second dose while exhibiting a favorable tolerability profile with lower rates of injection site reactions compared to the existing standard.

The Transition Toward Recombinant Subunit Vaccine Dominance is accelerating as new market entrants advance their candidates through regulatory milestones, challenging the monopoly of existing recombinant options and marking the definitive decline of live-attenuated vaccines. This trend is characterized by the expansion of the subunit class into global markets, driven by the need for robust supply chains and diversified sourcing to meet the demands of immunization programs. This shift is substantiated by recent regulatory progress; according to Jiangsu Recbio Technology Co., Ltd., in December 2025, in an announcement regarding the New Drug Application (NDA) for REC610, the candidate's application was officially accepted by the Center for Drug Evaluation, positioning it as a key challenger in the expanding recombinant subunit market.

Key Market Players

• GSK plc.
• Bausch Health Companies Inc.
• Renata Limited
• Novan, Inc.
• Teva Pharmaceuticals USA, Inc.
• Pfizer Inc.
• Apotex Inc.
• Sandoz Canada Inc.
• Novartis Pharmaceuticals Corporation

Report Scope

In this report, the Global Herpes Zoster Infection Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpes Zoster Infection Treatment Market, by Treatment Type:

• Prescription Treatment
• Supporting Treatment

Herpes Zoster Infection Treatment Market, by Route of administration:

• Oral
• Intravenous
• Others

Herpes Zoster Infection Treatment Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Herpes Zoster Infection Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpes Zoster Infection Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.